334LF, Scientist, Cellular Reprogramming and Engineering

Job Code 334LF

Description

Fate’s Cellular Reprogramming and Engineering Group is seeking a skilled and highly motivated cell biologist to support ongoing cellular reprogramming and engineering research to further the development of novel off-the-shelf cellular therapeutics for the treatment of cancer and other disorders. The successful candidate will be responsible for playing a key role in the research and development of the company’s induced pluripotent stem cell (iPSC) platform. Ideally, the candidate will have strong expertise in cell culture, culture of pluripotent cells, and genetic engineering of human cells using various editing tools. The position includes collaboration with internal R&D, process development, quality assurance, and regulatory groups and external partners including our renowned academic research collaborators. The position also has the opportunity to lead various programs from inception to regulatory filings, providing a unique experience to play a major role in product development of off-the-shelf cell therapies. This is a full-time position and located at our corporate headquarters in San Diego, CA.

Download a PDF of the job description for more details:

View PDF

For consideration send cover letter and curriculum vitae to: careers@fatetherapeutics.com and reference job 334LF.

About Fate Therapeutics, Inc.

Fate Therapeutics is a biopharmaceutical company dedicated to the development of programmed cellular immunotherapeutics for the treatment of cancer and immune disorders. The Company’s cell-based product candidate pipeline is comprised of off-the-shelf immuno-oncology therapeutics, including NK- and T-cell-based candidates derived from induced pluripotent cells, and immuno-regulatory therapeutics, including hematopoietic cell-based candidates for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing auto-reactive T cells of patients with auto-immune disorders. Its adoptive cell therapy candidates are based on the Company’s novel ex vivo cell programming approach, which it applies to modulate the therapeutic function and direct the fate of immune cells.